205results about "Omics" patented technology

Described herein are systems and methods for analyzing cells, including a method comprising: (a) forming a compartment within a fluid, wherein the fluid comprises a plurality of cells, wherein the compartment encloses a cell of the plurality of cells, and wherein the compartment physically separates the cell from an additional cell of the plurality of cells; (b) incubating the cell for about 1 minute to about 10 hours, wherein the cell is inside of the compartment during the incubating; and (c) performing an assay within the compartment, thereby analyzing the cell.

Described herein are methods for screening for a disease state. The method may include obtaining multiple data sets and identifying the disease state based on a combination of the data sets. The data sets may include biomolecule measurements obtained by multiple methods, such as through the use of particles and reference biomolecules.

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

To provide a 100% natural product comprising a natural matrix exhibiting emergence properties that enable re-establishment of correct metabolism, cancer treatment and support of tissue homeostasis in tissues infiltrated by cancer cells.SOLUTION: The product of the present invention, which serves to solve the above problems, is a natural matrix which, as demonstrated by the inventors, represents a native natural intelligence in itself, said natural intelligence being the only one capable of allowing physiological endogenous interconnections with other entities self-assembled in nature, such as human species. By modulating the tumor microenvironment and thus selectively inducing cancer cell mortality, said product achieves a reconstitution of conditions favorable to tissue homeostasis in tissues infiltrated by cancer cells. Indeed, the present invention allows a paradigm shift based on the transition from deterministic validation of properties to probabilistic validation based on functional redundancy logic, which will provide an industrially viable source of innovation for manufacturers in the field of 100% natural therapeutic or beneficial products.SELECTED DRAWING: None

Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.

A method for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding is disclosed.

The invention belongs to the technical field of biological materials and biological information, and provides a space phosphorylation modification omics detection method. According to the detection method disclosed by the invention, proteomics analysis can be carried out on trace sample phosphorylation, 4259 phosphorylation sites can be identified by 5 micrograms of peptide fragments, and the credibility of 3506 sites is greater than 0.75.

Provided herein are compositions and methods for the identification of an expression profile in a single cell or population of cells. Kits for use with the disclosed methods are also provided, including antibodies, with a unique molecular identifier and antibody identifier, and primers for amplification of the antibody identifier sequence.

The present invention relates to a 100% natural product consisting of natural matrices showing emerging properties, which allows to re-establish a correct metabolism in tissues infiltrated by cancer cells, adjuvating cancer treatment and tissue homeostasis. The product of the invention, as demonstrated by the inventors, is itself a natural matrix, representing native natural intelligence, said natural intelligence being the only capable to allow a physiological endogenous interconnection with other entities which are self-assembled in nature, such as the human species. By modulating tumor microenvironment and thus selectively inducing cancer cells mortality, the product achieves reconstitution of conditions favourable to tissue homeostasis in tissues infiltrated by cancer cells. Factually, the invention allows for a shift of paradigm based on the passage from a deterministic validation of properties to a probabilistic one based on functional redundancy logics, that will grant an industrially viable source of innovation for manufacturers in the field of 100% natural therapeutic or beneficial products.

Described herein are systems and methods for analyzing biological samples. The methods can include forming a plurality of compartments, wherein a compartment of the plurality of compartments may enclose a cell inside of a fluidic device. The methods can further include detecting an interaction between the cell and an additional cell within the fluidic device.

A group of diagnostic biomarkers usable for diagnosis of colorectal cancer or advanced colorectal adenoma (CRC / ACRA) is provided. The method for detecting CRC / ACRA using the group of diagnostic biomarkers is also provided. For example, the method is a non-invasive approach that may utilize serum samples for detecting colorectal cancer. Moreover, the method for detecting colorectal cancer may detect colorectal cancer of different stages (e.g., pre-cancer stage, early stage, middle stage, late stage). A kit for detecting CRC / ACRA is also provided.

Described herein is a method of diagnosing Lyme disease in a subject. The method includes determining a glycosylation profile of a protein whose glycosylation profile is associated with Lyme disease in a subject, and comparing the glycosylation profile of the protein with a predetermined glycosylation profile of the protein indicating free of Lyme disease or a predetermined glycosylation profile of the protein indicating Lyme disease. Further described herein is a method of treating and / or ameliorating Lyme disease in a subject. The method includes diagnosing Lyme disease in a subject and, if the subject is diagnosed to have Lyme disease, administering to the subject an effective amount of compound effective for treating Lyme disease. Further described herein is a method of evaluating a treatment for Lyme disease. The method includes comparing a glycosylation profile of the patient with glycosylation profiles associated with successful / unsuccessful treatments.

The present invention relates to a biomarker for diagnosing lung cancer and methods for providing artificial intelligence-based information for diagnosing lung cancer, and more particularly to a biomarker for diagnosing lung cancer, comprising kynurenine (KN), lysophosphatidylcholine 16:0 (LPC16), lysophosphatidylcholine 18:0 (LPC18), glutamic acid (Glu), hexanoyl-L-carnitine (HC), octanoyl-L-carnitine (OC), decanoyl-L-carnitine (DC), dodecanoyl-L-carnitine (DDC), myristoyl-L-carnitine (MC) and palmitoyl-L-carnitine (PC), a biomarker composition for diagnosing lung cancer, and a method for providing artificial intelligence-based information for diagnosing lung cancer using the biomarker. As a result of establishing an artificial intelligence-based algorithm model for lung cancer diagnosis using the biomarkers for lung cancer diagnosis selected in the present invention, it was confirmed that the ability to early screen lung cancer is 90.21% sensitivity and 93.03% specificity, which is very high accuracy compared to the existing lung cancer screening method, so the present invention can effectively provide information on lung cancer diagnosis.

Metastasis is a major cause of fatality and expense in cancer. Many metastatic patients express calcified, fibrotic, or deep-seated (lymph / Jung / brain) lesions that are not easily profiled. For such patients, decision-making regarding treatment selection is population-based and heavily reliant on standards of care and are not tailored to the individual's tumor. The present disclosure provides methods of identifying treatment protocols for cancer patients using released tumor cells (RTCs). Method described herein include isolating / enriching RTCs, profiling RTCs and comparing RTCs to reference RTC profile libraries.

The present invention includes compositions and methods useful for the detection of a mutational change, SNP, translocation, inversion, deletion, change in copy number, or other genetic variation within a sample of cellular genomic DNA or cell-free DNA (cfDNA). In some embodiments, the compositions and methods of the present invention provide an extremely high level of resolution that is particularly useful in detecting copy number variations in a small fraction of the total cfDNA from a biological sample (e.g., blood).

Disclosed herein are methods and compositions for the detection of biomarkers for cardiac diseases. Disclosed herein are sample collection devices comprising detection devices for heart failure. Disclosed herein are methods of detecting, monitoring, preventing, or treating heart failure.

The present invention relates to a method for determining the presence of prostate cancer or benign prostatic hyperplasia (BPH) in a subject. The method comprises: (i) determining the level of one or more biomarkers in a sample from the subject; and (ii) comparing the level of said one or more biomarkers with the level of said one or more metabolites in a control sample to determine whether prostate cancer or BPH is present in the subject. The prostate cancer biomarkers are selected from: 3-hydroxyhexadecanoylcarnitine, alpha lipoic acid and N- heptanoylglycine. The BPH biomarkers are selected from N-lsobutyl-2,4,8, 10,12- tetradecapentaenamide, PE-NMe2(24: 1 (15Z) / 20:5(5Z,8Z, 11 Z, 14Z, 17Z)), 1-Phosphatidyl-D- myo-inositol, L-Urobilin, 18-Carboxy-dinor-LTE4, Urobilin / Urobilinogen, 5,6-Dihydrothymine, N-Acetyl-D-Glucosamine 6-Phosphate and cholic acid.

The present invention relates to methods and compositions for diagnosing and enabling treatment of chronic kidney disease in a feline. In one embodiment, a method of diagnosing chronic kidney disease (CKD) in a feline can comprise measuring a normalized relative abundance of a first urine biomarker and determining if the feline has CKD, early-stage CKD, or late-stage CKD based on the normalized relative abundance.

The present invention relates to a 100% natural product consisting of natural matrices showing emerging properties, which allows to re-establish a correct metabolism in tissues infiltrated by cancer cells, adjuvating cancer treatment and tissue homeostasis. The product of the invention, as demonstrated by the inventors, is itself a natural matrix, representing native natural intelligence, said natural intelligence being the only capable to allow a physiological endogenous interconnection with other entities which are self-assembled in nature, such as the human species. By modulating tumor microenvironment and thus selectively inducing cancer cells mortality, the product achieves reconstitution of conditions favourable to tissue homeostasis in tissues infiltrated by cancer cells. Factually, the invention allows for a shift of paradigm based on the passage from a deterministic validation of properties to a probabilistic one based on functional redundancy logics, that will grant an industrially viable source of innovation for manufacturers in the field of 100% natural therapeutic or beneficial products.

The present invention relates to systems and methods for inductively coupled plasma (ICP) analysis, including mass cytometry. Inductively coupled plasma (ICP) analyzers use an ICP torch to generate a plasma that atomizes and ionizes a sample. Analysis of the atomic ions can be performed by atomic analysis, such as mass spectrometry (MS) or atomic emission spectrometry (AES). Particle-based ICP analysis includes analysis of particles, such as cells, beads, or laser ablation plumes, by atomizing and ionizing the particles in an ICP torch prior to atomic analysis. In mass cytometry, the mass tags of the particles are analyzed by mass spectrometry, such as ICP-MS. The systems and methods of the present application include one or more of an ICP load coil including annular fins, particle suspension sample introduction fluidics, and an ICP analyzer.

This invention discloses the application of extracellular vesicle membrane proteins in the preparation of diagnostic kits for early gastric cancer. Using proteomics technology and the EVArray platform, this invention screened a series of novel biomarkers for EV membrane proteins: transforming growth factor β1, annexin A2, tendinin N, phospholipase-like domain protein 8, transferrin, fibroblast activating protein α, and cadherin 5. Clinical trials have demonstrated the potential of this invention for early diagnosis and postoperative monitoring of gastric cancer (GC). Among these, transforming growth factor β1 and tendinin N showed the most significant value in the early diagnosis of GC.

The invention belongs to the technical field of environmental biology, and particularly relates to a key gene for degrading skatole by enterococcus haiseri ID05 and application of the key gene for degrading skatole by enterococcus haiseri ID05, and the test process of the key gene for degrading skatole by enterococcus haiseri ID05 is as follows: selecting an enterococcus haiseri IDO5 strain, an LB culture medium, an inorganic salt culture medium and reagent consumables and instruments required in the test process; the degradation rate of the enterococcus haiseri IDO5 on 100 mg / L of skatole in an inorganic salt culture medium reaches 67.01 + / -0.01%, and it is shown that the enterococcus haiseri IDO5 has the good degradation capacity on the skatole. Besides, the degradation rate of the IDO5 on skatole in sterilized pig manure wastewater reaches up to 96.10%, the degradation rate of the IDO5 on skatole in unsterilized pig manure wastewater is also 78.17%, and the enterococcus hirsuti IDO5 has good degradation capacity on skatole in pig manure wastewater and has good application potential in pig manure wastewater, so that when the pig manure wastewater is discharged, the enterococcus hirsuti IDO5 can be used for degrading the skatole in the pig manure wastewater. After being treated by enterococcus hirsuti IDO5, the wastewater can be discharged, so that the pollution to the environment is effectively reduced.

The invention discloses application of a reagent for detecting a plasma metabolism marker combination in preparation of a product for diagnosing breast cancer, and belongs to the field of breast cancer markers. According to the application of the reagent for detecting the plasma metabolism marker combination in preparing the product for diagnosing the breast cancer, the plasma metabolism marker combination comprises dehydroepiandrosterone sulfate, acylcarnitine 12: 0 and taurodeoxycholic acid. The plasma metabolism marker combination has high specificity, high sensitivity and non-invasiveness when being used for breast cancer detection, so that a subject can conveniently and safely receive detection, and the plasma metabolism marker combination is suitable for screening and detection of large-scale common people and is beneficial to early screening, early diagnosis and early treatment of breast cancer.

The present invention relates to a 100% natural product consisting of natural matrices showing emerging properties, which allows to re-establish a correct metabolism in tissues infiltrated by cancer cells, adjuvating cancer treatment and tissue homeostasis. The product of the invention, as demonstrated by the inventors, is itself a natural matrix, representing native natural intelligence, said natural intelligence being the only capable to allow a physiological endogenous interconnection with other entities which are self-assembled in nature, such as the human species. By modulating tumor microenvironment and thus selectively inducing cancer cells mortality, the product achieves reconstitution of conditions favourable to tissue homeostasis in tissues infiltrated by cancer cells. Factually, the invention allows for a shift of paradigm based on the passage from a deterministic validation of properties to a probabilistic one based on functional redundancy logics, that will grant an industrially viable source of innovation for manufacturers in the field of 100% natural therapeutic or beneficial products.

Alzheimer's disease is strongly linked to biological aging and bioenergetic abnormalities. Systemic dysregulation of metabolism is a hallmark of the physiological decline of tissues with age. We aimed to explore untargeted metabolomic profiling of blood samples from amyloid-positive people to distinguish individuals who progressed to cognitive decline from those who remained cognitively intact despite having amyloid deposits in the brain. A minimal signature of 9 metabolites identified decliners and non-decliners of cognitive function in participants with an amyloid load. These findings are of clinical importance as they suggest that a metabolic fingerprint may help to predict patients who will develop cognitive decline. Due to the high prevalence of brain amyloid-positivity in older adults, identifying adults who will have cognitive decline will enable the development of personalized and early interventions. The present invention relates to an in vitro method for predicting cognitive decline in a subject comprising the step of determining the level of at least one metabolite selected in the group consisting of 3-hydroxybutyrate, acetone, triglyceride 48:3, glucose, citrate, succinate, methionine, serine, sphingomyelin d18:1 / C26:0 in a biological sample obtained from the subject.

The present disclosure provides azetidine compounds of Formula I and their pharmaceutically acceptable salts, their compositions, and methods for their use in determining azetidine compound binding to proteins. The azetidine compounds are useful as probes, for monitoring diacylglycerol kinase activity, and for identifying druggable targets.